Provided by Tiger Trade Technology Pte. Ltd.

Quest Diagnostics

244.39
+3.091.28%
Post-market: 244.390.00000.00%19:30 EDT
Volume:1.26M
Turnover:307.88M
Market Cap:26.97B
PE:25.95
High:244.70
Open:240.33
Low:239.43
Close:241.30
52wk High:245.68
52wk Low:171.18
Shares:110.37M
Float Shares:110.00M
Volume Ratio:1.61
T/O Rate:1.15%
Dividend:3.32
Dividend Rate:1.36%
EPS(TTM):9.42
EPS(LYR):8.75
ROE:14.60%
ROA:6.40%
PB:3.59
PE(LYR):27.93

Loading ...

GUIDANCE: (DGX) Quest Diagnostics Expects Full Year 2026 Revenue Range $11.95B - $12.05B, vs. FactSet Est of $11.85B

MT Newswires Live
·
Jul 23

Quest Diagnostics reports Q2 adjusted EPS $3.12, consensus $2.82

TIPRANKS
·
Jul 23

Quest Diagnostics ups FY26 adjusted EPS view to $11.05-$11.25 from $10.63-$10.83

TIPRANKS
·
Jul 23

Quest Diagnostics Shares up 5.8% Premarket After Co Forecasts Annual Revenue, Profit Above Estimates

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Q2 FY26 Diluted EPS Rises 15% to 2.84; Revenue Increases 10.2% to 3.04 Billion

Reuters
·
Jul 23

Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate

Benzinga Earnings
·
Jul 23

Stock Track | Quest Diagnostics Soars 5.32% in Pre-market on Better-Than-Expected Q2 Revenue

Stock Track
·
Jul 23

Quest Diagnostics Outlook FY EPS USD 9.97-10.17

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Q2 Revenue USD 3,043 Million VS. Ibes Estimate USD 2,967 Million

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 23

Quest Diagnostics Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

The Bull Case For Quest Diagnostics (DGX) Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Simply Wall St.
·
Jul 17

Quest Diagnostics Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 17

Buy Rating Reaffirmed on Quest Diagnostics as ACA-Related Risks Seen as Manageable and Earnings Resilient

TIPRANKS
·
Jul 16

Earning Preview: Quest Diagnostics Q2 revenue is expected to increase by 9.09%, and institutional views are bullish

Earnings Agent
·
Jul 16

Quest Diagnostics Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 16

Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating

MT Newswires Live
·
Jul 16

Quest Diagnostics Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since June 2024

Dow Jones
·
Jul 15

Biovica Receives Ninth Work Order from Customer

Reuters
·
Jul 14